Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CET

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
01:11p KIMBERLY CLARK : Professional’s Supply Chain Team Inspired to Help Atlanta’s Homeless Children
01:11p PERNIX THERAPEUTICS : Drug Makers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Sucampo Pharma, and Pernix Therapeutics
01:11p ANALYSIS OF THE GLOBAL OMEGA-3 EPA + DHA INGREDIENTS MARKET : Growing End-application Demand Induced by Rising Health Awareness - Research and Markets
01:10p GENERAL ELECTRIC : GE profit up 36 percent, sales slow; affirms 2017 forecast
01:10p SCHLUMBERGER : Announces Fourth-Quarter and Full-Year 2016 Results
01:10p COUNCIL OF EUROPEAN UNION : Indicative programme - Agriculture and Fisheries Council, 23 January 2017
01:10p BLACKROCK COMMS INCOME INV TST : COMMODITIES INCOME INVESTMENT TRUST PLC - Net Asset Value(s)
01:10p BLACKROCK FRONTIERS INV TST : INVESTMENT TRUST PLC - Net Asset Value(s)
01:10p BLACKROCK SMALLER TRUST : Net Asset Value(s)
01:10p BLACKROCK NORTH AMERICAN INCOME : TRUST PLC - Net Asset Value(s)
Latest news
Advertisement
Hot News 
10.81%SYNTHOMER : Chemicals maker Synthomer sees 2016 profit ahead of estimates
-3.07%European shares ease before Trump inauguration
6.41%SDL : Translation software firm SDL sees full year results ahead of market expectations
0.70%CLOSE BROTHERS : sees strong first half, reports rise in loan book
0.51%China cuts reserve ratios for big five banks temporarily amid cash crunch-sources
Most Read News
05:38a Toshiba making preparations for sale of stake in chip business - sources
01/19 TESLA MOTORS : U.S. regulator finds no evidence of defects after Tesla death probe
05:54a WESTERN UNION : admits to aiding wire fraud, to pay $586 million
01/19 AMERICAN EXPRESS : AmEx profit misses estimates on higher marketing spend
12:16aDJNEWS HIGHLIGHTS : Top Energy News of the Day
Most recommended articles
01/17DJS&P 500, Nasdaq Futures -- Technical Analysis
07:10a GENERAL ELECTRIC : GE profit up 36 percent, sales slow; affirms 2017 forecast
07:07a Fairfax may sell 25 percent of India's ICICI Lombard in up to $1 billion deal - sources
06:45a Trading house says Samsung seeks $429 million in LCD panel supply dispute
06:40aDJLONDON MARKETS : FTSE 100 Wobbles As Wait-and-see Mode Sets In Before Trump Takes Office